Aya Karam1, Georges Mjaess2, Yara El Daccache1, Marialida Farah1, Samah Daou1, Simone Albisinni3, Hanane Kazzi4, Rebecca Hassoun1, George Bou Kheir3, Fouad Aoun3,5, Thierry Roumeguère3,5. 1. Department of Internal Medicine, Faculty of Medicine, Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon. 2. Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. gmjaess@gmail.com. 3. Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. 4. Department of Radiology, Saint Joseph Medical Center, Beirut, Lebanon. 5. Department of Urology, Institut Jules Bordet, Brussels, Belgium.
Abstract
PURPOSE: Urinary microbiota has been found to play a key role in numerous urological diseases. The aim of this systematic review is to depict the role of urinary microbiota in the pathogenesis, diagnosis, prognosis, and treatment of urological tumors, including bladder cancer (BCa), prostate cancer (PCa) and renal cell carcinoma (RCC). METHODS: A systematic PubMed and Scopus search was undergone from inception through June 2021 for studies investigating urinary microbiota alterations in urological tumors. Study selection followed the PRISMA statement. Phylum, family, genus and species of each bacterium in cancer patients and controls were recorded. RESULTS: Twenty-one studies with 1194 patients (748 cancer patients and 446 controls) were included in our final analysis. Certain bacterial phylum, family, genus, and species were more predominant in each of BCa, PCa and RCC patients compared to controls. Abundance and specificity of urinary microbiota were prognosticators for: (1) recurrence, distinguishing recurrent from non-recurrent BCa, (2) disease stage, distinguishing non-muscle invasive from muscle invasive BCa, and (3) disease grade, distinguishing high- vs. low-grade PCa and BCa. Dietary, environmental and geographic patterns influenced urinary microbiota. Urinary microbiota of benign prostatic hyperplasia was different from PCa. CONCLUSION: Urological cancer patients have an altered urinary microbiota compared to controls. This may predict recurrence, disease stage and disease grade of these tumors. Further prospective studies are needed to depict a potential influence on therapeutic outcomes.
PURPOSE: Urinary microbiota has been found to play a key role in numerous urological diseases. The aim of this systematic review is to depict the role of urinary microbiota in the pathogenesis, diagnosis, prognosis, and treatment of urological tumors, including bladder cancer (BCa), prostate cancer (PCa) and renal cell carcinoma (RCC). METHODS: A systematic PubMed and Scopus search was undergone from inception through June 2021 for studies investigating urinary microbiota alterations in urological tumors. Study selection followed the PRISMA statement. Phylum, family, genus and species of each bacterium in cancer patients and controls were recorded. RESULTS: Twenty-one studies with 1194 patients (748 cancer patients and 446 controls) were included in our final analysis. Certain bacterial phylum, family, genus, and species were more predominant in each of BCa, PCa and RCC patients compared to controls. Abundance and specificity of urinary microbiota were prognosticators for: (1) recurrence, distinguishing recurrent from non-recurrent BCa, (2) disease stage, distinguishing non-muscle invasive from muscle invasive BCa, and (3) disease grade, distinguishing high- vs. low-grade PCa and BCa. Dietary, environmental and geographic patterns influenced urinary microbiota. Urinary microbiota of benign prostatic hyperplasia was different from PCa. CONCLUSION: Urological cancer patients have an altered urinary microbiota compared to controls. This may predict recurrence, disease stage and disease grade of these tumors. Further prospective studies are needed to depict a potential influence on therapeutic outcomes.
Authors: Peter J Turnbaugh; Ruth E Ley; Micah Hamady; Claire M Fraser-Liggett; Rob Knight; Jeffrey I Gordon Journal: Nature Date: 2007-10-18 Impact factor: 49.962
Authors: Evann E Hilt; Kathleen McKinley; Meghan M Pearce; Amy B Rosenfeld; Michael J Zilliox; Elizabeth R Mueller; Linda Brubaker; Xiaowu Gai; Alan J Wolfe; Paul C Schreckenberger Journal: J Clin Microbiol Date: 2013-12-26 Impact factor: 5.948
Authors: Mark C Markowski; Stephen A Boorjian; Jeremy P Burton; Noah M Hahn; Molly A Ingersoll; Saman Maleki Vareki; Sumanta K Pal; Karen S Sfanos Journal: Eur Urol Date: 2019-01-15 Impact factor: 20.096
Authors: Tiago Antunes-Lopes; Luis Vale; Ana Margarida Coelho; Carlos Silva; Malte Rieken; Bogdan Geavlete; Tina Rashid; Sajjad M Rahnama'i; Jean Nicolas Cornu; Tom Marcelissen Journal: Eur Urol Focus Date: 2018-09-28
Authors: Daniel A Shoskes; Jessica Altemus; Alan S Polackwich; Barbara Tucky; Hannah Wang; Charis Eng Journal: Urology Date: 2016-03-09 Impact factor: 2.649
Authors: Huma Siddiqui; Karin Lagesen; Alexander J Nederbragt; Stig L Jeansson; Kjetill S Jakobsen Journal: BMC Microbiol Date: 2012-09-13 Impact factor: 3.605
Authors: Sahyun Pak; Sun-Young Kim; Sung Han Kim; Jae Young Joung; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Ho Kyung Seo Journal: Front Oncol Date: 2021-04-02 Impact factor: 6.244
Authors: Rajvinder Khasriya; Sanchutha Sathiananthamoorthy; Salim Ismail; Michael Kelsey; Mike Wilson; Jennifer L Rohn; James Malone-Lee Journal: J Clin Microbiol Date: 2013-04-17 Impact factor: 5.948